Avzivi? (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi? is the second biosimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsBio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company has filed an Investigational New Drug Application (IND) with the China National Medical Products Administration (NMPA) for the Comp...
Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2018 San Antonio Breast Cancer Symposium (SABCS) taking place December 4 - 8, 2018 in San Antonio, ...
Guangzhou, China --(BUSINESS WIRE)-- Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that patient dosing has begun ina Phase I clinical study of BAT4306F in relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphomapatients. BAT4306F is an ADCC-enhanced CD20 monocl...
